About

Peggy Soule Odegard, BS Pharm, PharmD, CDES, is the Lynn and Geraldine Brady Endowed Professor of Pharmacy at the University of Washington School of Pharmacy. She served as the Interim Dean for the School of Pharmacy in 2022-2023 and is an active pharmacist practitioner. Dr. Odegard earned her Doctor of Pharmacy and Bachelor of Science in Pharmacy degrees from the University of Washington. Her research and teaching focus on diabetes care, pharmacy practice advancement, interprofessional education, and leadership. She oversees the UW School of Pharmacy Doctor of Pharmacy program and is an advanced diabetes care pharmacist clinician, providing outreach and community-based education to older adults and those affected by diabetes, while mentoring students. Dr. Odegard has published more than 60 refereed manuscripts and book chapters and regularly presents her work nationally. Her prior experience includes serving as the Clinical Pharmacy Manager for a regional health system, where she gained substantial experience in organizational leadership, change management, quality improvement, and the implementation of pharmacy practice services.

Research topics

• Political Science
• Medicine
• Nursing
• Medical education
• Public relations
• Psychiatry
• Psychology
• Business
• Immunology
• Family medicine

Selected publications

• A closer look at the role of apology in error disclosure: a simulation study

  Frontiers in Health Services · 2025-06-03

  articleOpen access

  Background: The importance of open communication following harmful medical errors is widely accepted including the role of authentic apology. Yet, disclosure conversations remain difficult for clinicians and offering an authentic apology is challenging. Purpose: To better understand how clinicians can improve disclosures and apologies by using simulation to observe the approach clinicians use in the initial disclosure, where and when apologies occur within these conversations, what content apologies are linked with, who apologizes, and how apologies differ by their timing within the overall disclosure conversation. Methods: Forty-nine simulations of physician-nurse teams from the U.S. and Canada were videotaped planning and disclosing either a medical or surgical error to a patient-actress. Data from the disclosure portions were coded and analyzed using Atlas-Ti to describe the communication approach clinicians use when disclosing errors and the occurrence and timing of apologies within those disclosures. Results: Ninety-eight clinicians participated: 38 MD-RN teams from the U.S. and 11 from Canada. Of the 49 total simulated error disclosures, 30 involved medical teams disclosing an insulin overdose; 19 were surgical teams disclosing a lost specimen. The average length of the error disclosure conversations was 9.8 minutes (range = 6.1-14.2 min) and tended to follow a similar roadmap. On average, teams offered 2-3 apologies per disclosure (range = 0-9). These apologies occurred at all points during the disclosures and were offered by both physician and nurse participants. Discussion: Clinicians approached the initial disclosure conversations by addressing nine topics in a relatively consistent order. Apologies occurred throughout the disclosures. With opening comments, clinicians apologized to foreshadow bad news; with closing comments, they linked their remorse to broader professional and organizational goals around patient safety and transparency. Within the disclosure, clinicians sometimes linked the apology to their own emotional experience. More frequently, they linked apologies to the patient's emotional response, which may be more effective to ensure that patients hear that the clinicians' remorse is linked to patient suffering rather than clinician discomfort. To improve these difficult discussions, training materials and guidelines for communicating with patients after harm should reflect the complex role that apologies play.

  PublisherOA PDFDOI

• Provision of Mental and Behavioral Health Supports and Services by Pharmacists in Washington State

  Community Mental Health Journal · 2025-01-03 · 2 citations

  article
  PublisherDOI

• Biguanides

  American Diabetes Association eBooks · 2025-08-22

  book-chapter1st authorCorresponding

  Biguanides1 in some form have been used since medieval times. French lilac, or goat’s rue (galega officinalis), was used as a folk treatment for diabetes in southern and eastern Europe. Later, galega officinalis was found to be rich in the compound guanidine. In 1918, the hypoglycemic activity of guanidine was confirmed. Unfortunately, guanidine was too toxic for human clinical use, but its chemical congeners, such as the alkyldiguanide synthalin A, were introduced in the early 1920s. Further analysis continued with the biguanide group in the 1920s; however, clinical use of these compounds was not pursued. The compounds fell into disfavor because of the discovery and availability of insulin products.

  PublisherDOI

• Leveraging Change Management Principles to Implement Computer-Based Assessments in a PharmD Program

  American Journal of Pharmaceutical Education · 2025-11-01

  articleOpen accessSenior author
  PublisherDOI

• Thiazolidinediones

  American Diabetes Association eBooks · 2025-08-22

  book-chapterSenior author

  The first thiazolidinedione (TZD), ciglitazone, was synthesized in 1982. It was soon thereafter discovered that ciglitazone reduced insulin resistance in obese and diabetic animals. Because of their effects on insulin resistance, TZDs have been developed as pharmacological agents for the management of T2D, although they were initially synthesized as potential lipid-reducing agents. Since their discovery, three TZDs have been introduced to the market in the U.S.: troglitazone (Rezulin), rosiglitazone (Avandia), and pioglitazone (Actos). In 2013, the FDA removed the Risk Evaluation and Mitigation Strategy (REMS) program and lifted restrictions on prescribing and dispensing rosiglitazone after concluding that data did not show a higher risk of heart attack with rosiglitazone compared with the standard T2D drugs of metformin and sulfonylurea. Currently, pioglitazone is the only TZD available worldwide.

  PublisherDOI

• A Coordinated Approach to School-Wide Faculty & Staff Development

  American Journal of Pharmaceutical Education · 2024-09-01

  articleOpen accessSenior author
  PublisherDOI

• Strengthening the Behavioral and Mental Health Workforce Through Pharmacy Education

  American Journal of Pharmaceutical Education · 2024 · 1 citations

  • Political Science
  • Medical education
  • Psychology

  Objective: The United States is facing difficulties ensuring a sufficient mental health workforce, including pharmacists with specialized training in psychiatry. The objective is to describe a pharmacy school’s approach to enhance pre- and postgraduate training in psychiatry to address workforce needs.

  PublisherDOI

• Thiazolidinediones

  American Diabetes Association eBooks · 2024-01-01

  book-chapterSenior author

  Highlights: Introduction Pharmacology Treatment Advantages/Disadvantages Therapeutic Considerations Monographs References

  PublisherDOI

• Biguanides

  American Diabetes Association eBooks · 2024-01-01

  book-chapter1st authorCorresponding

  Introduction Pharmacology Treatments Advantages/Disadvantages Therapeutic Considerations Dosage and Administration Combination Products Monographs References

  PublisherDOI

• A 2023 Washington State pharmacist workforce survey: Employment and patient care roles

  Journal of the American Pharmacists Association · 2024-12-17 · 2 citations

  articleOpen access
  PublisherOA PDFDOI

Frequent coauthors

• Maureen E. Chomko

  16 shared

• Alison B. Evert

  16 shared

• Jennifer L. Bacci

  University of Washington

  15 shared

• Kam L. Capoccia

  14 shared

• Stephen M. Setter

  American Association of Colleges of Pharmacy

  9 shared

• Nancy A. Letassy

  University of Oklahoma

  9 shared

• Sarah E. Shannon

  9 shared

• Lynne Robins

  University of Washington Medical Center

  7 shared

Education

• Other

  University of Washington

• Other

  University of Washington